Current Status of Chimeric Antigen Receptor Engineered T Cell-Based and Immune Checkpoint Blockade-Based Cancer Immunotherapies

Cancer Immunology, Immunotherapy - Germany
doi 10.1007/s00262-017-2007-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

JAMA Oncology
Cancer ResearchOncology
2018English

Chimeric Antigen Receptor T-Cells

Cancer Journal
Cancer ResearchOncology
2015English

Selinexor‐based Regimens for the Treatment of Myeloma Refractory to Chimeric Antigen Receptor T Cell Therapy

British Journal of Haematology
Hematology
2020English

Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Molecular Therapy - Oncolytics
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Chimeric Antigen Receptor T Cell Therapies for Multiple Myeloma

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma

International Journal of Hematology
Hematology
2020English

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

English

An Introduction to Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Human Cancer

American Journal of Hematology
Hematology
2019English

Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies

Cancer Cell
Cancer ResearchOncologyCell Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy